TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies
Nick IppolitoDuring the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research. Read more
Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations
Nick IppolitoDuring TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression. Read more
Revisit all your favorite moments from #TTLC23 in our photo gallery. Read more
Conference chairs Drs. Paul Bunn, Charu Aggarwal, Lecia Sequist, and Joel Neal discuss what makes this meeting unique and share program highlights in a recent Q&A with ILCN. Read more
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership. Read more
Increasing Evidence Demonstrates the Usefulness of ctDNA
Christian Rolfo, MD, PhD, MBA, Drhc+more
LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection. Read more
During the Closing Ceremony, five early-career, trainee, or resident investigators were honored for presenting at LALCA 2023. Read more
Latin America Conference Attendees Gather Face-to-Face for First Time Since 2019
Erin JungmeyerAs LALCA 2023 gets under way in Montevideo, Uruguay, hear from chairs Drs. Luis Ubillos, Mario Varangot, Clarissa Mathias, and Carlos Barrios about the science that will be discussed. Read more
Despite Evidence of Benefit, Developing Countries Often Lack Routine Lung Cancer Screening Practices
Ricardo Sales dos Santos, MD, PhDExpert panel to discuss challenges and opportunities for increasing LDCT screening in Latin America during LALCA 2023. Read more
Presidential Symposium Features Best of Abstract Submissions
Luis E. Raez, MD+more
Highlighted studies explore the association of TP53 mutations with inferior prognosis in NSCLC patients of African ancestry, the possibilities for next-generation sequencing to guide therapy, and the use of a 12-gene expression panel to predict treatment benefit. Read more